Lisinopril – inhibitor of angiotenzinpreobrazovatelny enzyme (APF).

Indications

• Essential hypertensia.
• Heart failure (symptomatic treatment).
• Acute myocardial infarction (short-term treatment (6 weeks) of hemodynamically stable patients not later than in 24 h after an acute myocardial infarction).
• Treatment of an initial nephropathy at the patients sick with diabetes of the II type, with arterial hypertension.

Structure

• active ingredient: lisinopril;
• 1 tablet contains a lisinopril dihydrate in terms of lisinopril of 5 mg;
• other components: calcium hydrophosphate, mannitol (E 421), starch corn, magnesium stearate, silicon dioxide colloidal anhydrous.

Contraindication

• Hypersensitivity to acting or to excipients of drug.
• Quincke's disease in the anamnesis connected with preliminary treatment by other APF inhibitors.
• Hereditary or idiopathic Quincke's disease.
• Stenosis of an aorta or the mitral valve or a hypertrophic cardiomyopathy with disturbance of a hemodynamics.
• Primary hyper aldosteronism.
• Renal artery stenosis (bilateral or unilateral).
• Cardiogenic shock.
• State with an unstable hemodynamics after an acute myocardial infarction.
• Use to the patients who are on a hemodialysis with use of high-flowing membranes (for example, AN 69).
• creatinine Level in blood serum> 220 µmol/l.
• Period of pregnancy or the woman who are going to become pregnant.

Side effects, as a rule, are mild and short-term

, the termination of treatment is necessary in extreme cases.

from the system of blood: suppression of activity of marrow, anemia, thrombocytopenia, leukopenia, neutropenia, agranulocytosis, hemolytic anemia, lymphadenopathy.

from the immune system: autoimmune disease, angioedy.

from an endocrine system a syndrome of inadequate secretion of antidiuretic hormone.

Metabolic disturbances: hypoglycemia.

from nervous system: dizziness, headache, paresthesia, vertigo, taste disorder, syncope.

from mentality: change of mood, sleep disorder, confusion of consciousness, depression.

from a cardiovascular system: cardiopalmus; tachycardia; the myocardial infarction is possible as a complication of excessive arterial hypotension at patients with high risk; the orthostatic phenomena (including arterial hypotension); disturbance of cerebral circulation is possible as a complication of excessive arterial hypotension at patients with high risk; Reynaud's phenomenon.

Route of administration

to Accept 1 time a day, in one and too time, irrespective of meal.

Feature of use

Use during pregnancy or feeding by a breast

Medicine is contraindicated for use to the pregnant women or women planning pregnancy. If during treatment the pregnancy is confirmed by this medicine, its use should be stopped and if it is necessary, to replace with other medicine allowed for use to pregnant women.

As information on a possibility of use of lisinopril when feeding by a breast is absent, intake of lisinopril is not recommended.

Children

do not use Drug to children.

Ability to influence speed of response at control of motor transport or other mechanisms

Considering possibility of dizziness and development of fatigue, lisinopril can affect ability of driving and work with other mechanisms, especially in an initiation of treatment. Therefore it is necessary to refrain from control of motor transport and work with other mechanisms before establishment of individual reaction to drug.

Data on overdose of people are limited to

. The symptoms connected with overdose of APF inhibitors can include arterial hypotension, circulator shock, disturbance of electrolytic balance, a renal failure, a hyperventilation, tachycardia, a cardiopalmus, bradycardia, dizziness, concern and cough.

Treatment. Symptomatic therapy. Except the general measures directed to removal of lisinopril from an organism (gastric lavage, intake of adsorbents and potassium sulfate within 30 minutes after intake of lisinopril), control of vital indicators and their adjustment in intensive care unit is necessary. Continuous control of level of electrolytes and concentration of creatinine in blood serum is necessary.

Recommended treatment at overdose is administration of standard saline solution and replenishment of volume of liquid. If as a result of these measures the desirable result was not achieved, intravenous administration of a catecholamine is necessary. It is also necessary to take into account treatment by angiotensin II.

Bradycardia can be lowered by intake of atropine. It is necessary to consider the possibility of installation of a pacemaker at development of bradycardia, persistent to treatment.

can remove Lisinopril with

from the general blood-groove by means of a hemodialysis. At dialysis it is necessary to avoid use of poliakrilnitrilovy membranes with a high density of a stream.

Storage conditions

to Store

in original packing at a temperature above 25 °C.

to Store

out of children's reach.